Gilead’s Antiviral Remdesivir Prevents Disease Progression in Monkeys with COVID-19
|
By HospiMedica International staff writers Posted on 21 Apr 2020 |
|
Image: Gilead’s Antiviral Remdesivir Prevents Disease Progression in Monkeys with COVID-19 (Photo courtesy of Gilead Sciences)
A study by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases {(NIAID) Rockville, MD, USA} has found that early treatment with Gilead Sciences’ (Foster City, CA, USA) remdesivir significantly reduced clinical disease and damage to the lungs of rhesus macaques infected with SARS-CoV-2. The study was designed to follow dosing and treatment procedures used for hospitalized COVID-19 patients being administered the experimental antiviral drug in a large, multi-center, clinical trial
The study involved two groups of six rhesus macaques, with one group receiving remdesivir and the other animals being served as an untreated comparison group. The scientists infected both the groups with SARS-CoV-2 and administered an intravenous dose of remdesivir to the treatment group after 12 hours, followed by a daily intravenous booster dose for the next six days. The scientists timed the initial treatment to occur shortly before the virus reached its highest level in the animals’ lungs.
The scientists examined all animals 12 hours after the initial treatment and found the six treated animals to be in significantly better health than the untreated group, with the trend continuing over the course of the seven-day study. One of the six treated animals exhibited mild breathing difficulty, whereas all the six untreated animals showed rapid and difficult breathing. The amount of virus found in the lungs of the animals in the treatment group was significantly than those in the untreated group, and SARS-CoV-2 caused less damage to the lungs of the treated animals than the untreated animals.
The scientists believe that the data supports initiating remdesivir treatment in COVID-19 patients as early as possible to achieve maximum treatment effect, although they have noted that while remdesivir helped prevent pneumonia, it did not reduce virus shedding by the animals.
Related Links:
Gilead Sciences
National Institute of Allergy and Infectious Diseases
The study involved two groups of six rhesus macaques, with one group receiving remdesivir and the other animals being served as an untreated comparison group. The scientists infected both the groups with SARS-CoV-2 and administered an intravenous dose of remdesivir to the treatment group after 12 hours, followed by a daily intravenous booster dose for the next six days. The scientists timed the initial treatment to occur shortly before the virus reached its highest level in the animals’ lungs.
The scientists examined all animals 12 hours after the initial treatment and found the six treated animals to be in significantly better health than the untreated group, with the trend continuing over the course of the seven-day study. One of the six treated animals exhibited mild breathing difficulty, whereas all the six untreated animals showed rapid and difficult breathing. The amount of virus found in the lungs of the animals in the treatment group was significantly than those in the untreated group, and SARS-CoV-2 caused less damage to the lungs of the treated animals than the untreated animals.
The scientists believe that the data supports initiating remdesivir treatment in COVID-19 patients as early as possible to achieve maximum treatment effect, although they have noted that while remdesivir helped prevent pneumonia, it did not reduce virus shedding by the animals.
Related Links:
Gilead Sciences
National Institute of Allergy and Infectious Diseases
Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Stereotactic QA Phantom
StereoPHAN
New
Endoscopic Surgical Medical Monitor
E2421
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
Innovative Risk Score Predicts Heart Attack or Stroke in Kidney Transplant Candidates
Heart researchers have utilized an innovative risk assessment score to accurately predict whether patients being evaluated for kidney transplants are at risk for future major cardiac events, such as a... Read more
AI Algorithm Detects Early-Stage Metabolic-Associated Steatotic Liver Disease Using EHRs
Liver disease, which is treatable when detected early, often goes unnoticed until it reaches advanced stages. Metabolic-associated steatotic liver disease (MASLD), the most prevalent form of liver disease,... Read moreCritical Care
view channel
Novel Coating Significantly Extends Longevity of Implantable Biosensors
Wearable and implantable biosensors capable of accurately detecting biological molecules in a non-invasive or minimally invasive way offer enormous potential for monitoring patients’ health and their responses... Read more
Nanogel-Based Drug Delivery Technology to Improve UTI Treatment
Urinary tract infections (UTIs) are not only widespread and costly but also highly debilitating, significantly impacting the quality of life for those affected. The antibiotics commonly used to treat UTIs... Read more
New IV Pole Improves Safety and Ease of Administering IV Medications at Hospital Bedside
Preventable medication errors affect around 500,000 hospitalized patients in the U.S. every year. A significant portion of these errors occur with intravenous (IV) smart pumps, which require a precise... Read more
Surgical Techniques
view channel
Easy-To-Apply Gel Could Prevent Formation of Post-Surgical Abdominal Adhesions
Surgical adhesions are a frequent and often life-threatening complication following open or laparoscopic abdominal surgery. These adhesions develop in the weeks following surgery as the body heals.... Read more
Groundbreaking Leadless Pacemaker to Prevent Invasive Surgeries for Children
Leadless pacemakers marked a significant advancement in cardiac care, primarily because traditional pacemakers are dependent on leads, which are prone to breakage over time. Currently, two FDA-approved... Read more
Patient Care
view channel
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more
Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more
Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
A groundbreaking innovation enables hospitals to significantly improve instrument processing time and throughput in operating rooms (ORs) and sterile processing departments. Turbett Surgical, Inc.... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read more
Point of Care
view channel
Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour
Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Smartphone-Enabled, Paper-Based Quantitative Diagnostic Platform Transforms POC Testing
Point-of-care diagnostics are crucial for public health, offering rapid, on-site testing that enables prompt diagnosis and treatment. This is especially valuable in remote or underserved regions where... Read moreBusiness
view channel
Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business
Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA), has announced that its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic... Read more
